印度一家研究中心对婴儿患者(137只眼睛)随访6年，结果显示，玻璃体内注射贝伐单抗可有效治疗重度或阈值期早产儿视网膜病变(ROP)和眼并发症，不良结局罕见。“我们感觉玻璃体内注射贝伐珠单抗对阈值期ROP有效，特别是对侵袭性较强的前视网膜病变和世界上ROP发生于较大婴儿的地区。”介绍这项研究的Alay S. Banker医学博士(印度艾哈迈德巴哈市Banker视网膜医院和激光中心)说。

　　PA084

　　Safety, Efficacy, and Adverse Events of Intravitreal Bevacizumab Injection Without Laser for ROP: Six-year Follow-up Results With Anatomical, Functional, OCT, and Neurodevelopmental Analysis

　　Purpose: To evaluate 6-year safety and efficacy of intravitreal bevacizumab (IB) in retinopathy of prematurity (ROP).

　　Methods: Prospective study of 137 eyes with ROP treated with IB without laser.

　　Results: ROP regression, OCT, functional evaluation (electroretinogram [ERG], visual evoked potential [VEP]) and neurodevelopmental anlysis (developmental quotient [DQ] score) were performed at 6 years.

　　Results: All eyes showed regression of ROP and normal macula on OCT. Eight of 137 (6%) had persistent peripheral avsacular retina. There was normal retinal function (normal-VEP and ERG) and normal neurodevelopment score (normal DQ).

　　Conclusion: Our long-term follow-up study shows that IB seems to be safe and effective in treatment of ROP.